XNAS · Healthcare · Biotechnology
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | Q1 2026 | -0.85 | -0.95 | -11.76% | $0 | ❌ Miss | +3.83% | -10.19% | — |
| 2026-03-10 | Q4 2025 | -0.83 | -0.84 | -1.20% | $0 | ❌ Miss | +0.18% | +3.95% | +11.84% |
| 2025-11-12 |
| Q3 2025 |
| -0.85 |
| -0.88 |
| -3.53% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.80 | -0.87 | -8.75% | $0 | ❌ Miss | +18.47% | -6.97% | +25.78% |
| 2025-05-08 | Q1 2025 | -0.66 | -0.83 | -25.76% | $0 | ❌ Miss | — | — | — |
| 2025-03-24 | Q4 2024 | -0.62 | -0.66 | -6.45% | $0 | ❌ Miss | — | — | — |
| 2024-11-12 | Q3 2024 | -0.91 | -0.92 | -1.10% | $0 | ❌ Miss | — | — | — |
| 2024-08-29 | Q2 2024 | -4.40 | -22.00 | -400.00% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.